close
Add to watchlist
Ligand Pharmaceuticals Inc (LGND) Healthcare
Ligand Pharmaceuticals Incorporated, a biotechnology company, focuses on the discovery and development of pharmaceuticals for the critical unmet medical needs in the United States. It offers Avinza for the treatment of chronic pain; and Eltrombopag/Promacta for the treatment of thrombocytopenia in patients with chronic immune thrombocytopenic purpura (ITP). The company's products under food and drug administration review comprise Bazedoxifene and Lasofoxifene to treat osteoporosis; and Eltrombopag/Revolade for the treatment of ITP. Its products under Phase III include Bazedoxifene/Premarin for menopausal symptoms; and Eltrombopag to treat hepatitis C and chronic liver disease. The company's products under Phase II consist of PS433540, a dual acting receptor agonist that targets the angiotensin and endothelin receptors; LGD-4665 for the treatment of ITP; Eltrombopag to treat oncology related thrombocytopenia; PS291822 to prevent COPD and asthma; and PS540446 for the treatment of psoriasis and atherosclerosis. Ligand's products under Phase I comprise Eltrombopag to treat oncology related thrombocytopenia; PS095760 for leukemia; PS386113 and PS873266 for inflammation; PS948115 to treat respiratory diseases; PS248288 for the treatment of metabolic related diseases; and PS178990 for muscle wasting. Its products under preclinical stage consist of BACE inhibitor for the treatment of Alzheimer's disease; LGD-4033 for muscle wasting; CCR1 antagonist and glucocorticoid receptor modulator for inflammation; Erythropoietin receptor agonist for hematological indications; and receptor modulators for androgen independent prostate cancer. Ligand has research and development collaborations with pharmaceutical companies, including GlaxoSmithKline; Wyeth; Pfizer, Inc.; Schering-Plough Ltd.; Bristol-Myers Squibb Company; Cephalon, Inc.; Celgene Corporation; and Trevena. The company was founded in 1987 and is based in San Diego, California.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 16.14 |
| Volume | 99718 |
| Volume Avg | 88336 |
| 52 Week High | 16.37 |
| 52 Week Low | 9.16 |
| PE | 31.23 |
| PE (group average) | 39 |
| EPS Year | 0.52 |
| EPS change Q/Q | 108.7% |
| EPS change Q/Q Yr ago | -1000% |
| EPS change Q/Q next Q est | -1000% |
| EPS change Y/Y | -70% |
| REV change Q/Q | 0% |
| REV change Q/Q Yr ago | -35% |
| EPS next Q est | -0.01 |
| EPS next Y est | 0.35 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |